Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Nippon Med Sch ; 84(6): 291-293, 2017.
Article in English | MEDLINE | ID: mdl-29279560

ABSTRACT

We report a case of increased prothrombin time-international normalized ratio (PT-INR) when crizotinib and warfarin were co-administered. A 74-year-old Japanese woman presented to the hospital with dyspnea, and was diagnosed with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Three years after surgical resection of the tumor, the patient started crizotinib because of the recurrence of NSCLC. She received 2 mg/day warfarin due to a medical history of cerebral infarction and chronic atrial fibrillation. Before crizotinib initiation, the patient's PT-INR was 2.60. After 7 days of daily doses of crizotinib, the patient's PT-INR increased to 3.65. This case report provides the first evidence of a drug interaction between crizotinib and warfarin.


Subject(s)
Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , International Normalized Ratio , Lung Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , Prothrombin Time , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Pyridines/administration & dosage , Pyridines/adverse effects , Warfarin/administration & dosage , Warfarin/adverse effects , Aged , Carcinoma, Non-Small-Cell Lung/blood , Crizotinib , Drug Interactions , Drug Therapy, Combination/adverse effects , Female , Humans , Lung Neoplasms/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...